Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears

By Adé Hennis – Mar 21, 2026 at 10:17PM ESTKey PointsOne of Maze Therapeutics' executives exercised and sold 30,000 shares on March 10, 2026, generating gross proceeds of ~$1.51 million at a weighted-average price of ~$50.45 per share.Bernstein retains 267,407 shares in stock options, which can be converted to Common Stock.On March 10, 2026, Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics (MAZE 2.83%), reported the exercise of 30,000 stock options and immediate sale of the underlying common shares for ~$1.51 million, according to a SEC Form 4 filing. Transaction summaryMetricValueShares sold (direct)30,000Transaction value~$1.5 millionPost-transaction shares (direct)0Transaction value based on SEC Form 4 weighted average purchase price ($50.45).Key questionsHow does this transaction affect Bernstein's direct equity ownership in Maze Therapeutics?Bernstein's direct common stock holdings were reduced from 30,000 shares to zero following the option exercise and immediate sale, eliminating his direct ownership in this share class.What is the context of this transaction?The transactions were part of a Rule 10b5-1 trading plan that allows insiders to sell shares at a predetermined date, so the sales were scheduled in advance. ExpandNASDAQ: MAZEMaze TherapeuticsToday's Change(-2.83%) $-1.40Current Price$48.03Key Data PointsMarket Cap$2.3BDay's Range$47.76 - $50.7052wk Range$6.71 - $53.65Volume1.3MAvg Vol484KGross Margin-1304.00%Company overviewMetricValuePrice$48.03Market capitalization$2.31 billionNet Loss (TTM)$101.46 million1-year price change295.63%* Price and 1-year price change calculated using March 21, 2026 as the reference date. Company snapshotMaze Therapeutics is a clinical-stage biotechnology company that develops small-molecule precision medicines targeting renal (kidney), cardiovascular, and metabolic diseases, as well as obesity. Its lead candidate medicines include ones that help with kidney disease. What this transaction means for investorsBernstein’s sale shouldn’t concern investors, as it was part of a 10b5-1 trading plan that allows insiders to prearrange the purchase or sale of shares. And even though he doesn’t hold any direct shares, he still holds 267,407 stock options after the sales were conducted. Barely over a year removed from its IPO, Maze Therapeutics’ stock is still rising, having now increased in price for 11 consecutive months (as of March 21, 2026). There have been many instances in which, once a company has its IPO and share prices shoot up following the market debut, they fall back, and the price settles and becomes less volatile for a few months, if not years. But for Maze, its stock hasn’t showed much signs of slowing down yet. MAZE is currently considered a strong buy among Wall St analysts and continues to advance in clinical trials for multiple medicines. Still, investors may want to be wary of a potential brief drawdown amid so much significant bullish momentum, especially with the company’s upcoming Q4 earnings report for fiscal year 2025 scheduled for April 6. Read NextFeb 16, 2026 •By Adé HennisMaze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to SurgeFeb 1, 2026 •By Adé HennisMaze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's StockStocks MentionedMaze TherapeuticsNASDAQ: MAZE$48.03(-2.83%)-$1.40*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.